According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall ...

Ahmedabad: Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration ...

Investigators examined overall survival among real-world patients with metastatic prostate cancer (mCSPC) initiating enzalutamide vs apalutamide.

Wednesday, Johnson & Johnson (NYSE:JNJ) revealed results from a head-to-head study of Erleada (apalutamide) compared to ...

(NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the ...

Zydus Lifesciences on Wednesday said it has received approval from the US health regulator to produce a generic prostate ...

Zydus Lifesciences receives USFDA approval to manufacture Enzalutamide tablets, a generic prostate cancer treatment drug, for ...

Johnson & Johnson's (JNJ) prostate cancer therapy Erleada outperforms rival treatment from Pfizer (PFE) stellas (ALPMF) in ...

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients ...

BARCELONA, Spain — Adding bone-targeting radium-223 (Ra223) to the androgen receptor pathway inhibitor enzalutamide (Xtandi) in patients with metastatic castration-resistant prostate cancer and ...